EVEREST MEDICINES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.65 HKD | +2.28% |
|
+14.39% | +17.94% |
| 04-25 | Everest Medicines' Loss Widens in 2023 | MT |
| 03-28 | Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 673M 92.92M 727M 7.44B | Sales 2025 * | 1.52B 210M 1.64B 16.82B | Capitalization | 7.3B 1.01B 7.88B 80.66B |
|---|---|---|---|---|---|
| Net income 2024 * | -623M -85.98M -673M -6.89B | Net income 2025 * | -151M -20.84M -163M -1.67B | EV / Sales 2024 * | 9.82 x |
| Net cash position 2024 * | 687M 94.81M 742M 7.59B | Net cash position 2025 * | 757M 104M 818M 8.36B | EV / Sales 2025 * | 4.3 x |
| P/E ratio 2024 * |
-11.5
x | P/E ratio 2025 * |
-47.6
x | Employees | 432 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 58.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Everest Medicines Limited
More recommendations
More press releases
| 1 day | +2.28% | ||
| 1 week | +14.39% | ||
| Current month | +4.89% | ||
| 1 month | +12.56% | ||
| 3 months | +43.15% | ||
| 6 months | -5.01% | ||
| Current year | +17.94% |
1 week
21.40
24.80
1 month
21.3027.20
Current year
14.3430.65
1 year
10.3232.20
3 years
5.9879.90
5 years
5.98104.80
10 years
5.98104.80
| Managers | Title | Age | Since |
|---|---|---|---|
Yong Qing Luo
CEO | Chief Executive Officer | 54 | 18/09/22 |
Ian Ying Woo
PSD | President | 51 | 30/11/18 |
Michael Berry
CTO | Chief Tech/Sci/R&D Officer | 59 | 14/06/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yi Fan Li
BRD | Director/Board Member | 55 | 31/08/20 |
Honggang Feng
BRD | Director/Board Member | 59 | 02-08 |
Wei Fu
CHM | Chairman | 42 | 30/06/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.75% | 4 M€ | -27.92% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +1.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 24.65 | +2.28% | 4,301,600 |
| 25/04/24 | 24.1 | +2.55% | 3,363,688 |
| 24/04/24 | 23.5 | -1.26% | 1,919,996 |
| 23/04/24 | 23.8 | +1.93% | 3,442,191 |
| 22/04/24 | 23.35 | +8.35% | 3,674,373 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am
More quotes
Everest Medicines Ltd is a China-based company principally engaged in the licensing, clinical development and commercialization of therapies to address critical unmet medical needs. The Company is focusing on the research and development of innovative drug candidate. The Company built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The Company mainly provides its products and services in Greater China and other emerging Asia Pacific markets.
Sector
Pharmaceuticals
Calendar
21/06/2024
- CMBIS Healthcare Virtual Corporate Day
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
22.82
CNY
Average target price
25.92
CNY
Spread / Average Target
+13.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.94% | 1.01B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 1952 Stock
